Анализа корелације односа Th17/Treg, LCDC-2, IP-10 и функције јетре код пацијената са AIH
Однос Th17/Treg, LCDC-2, IP-10 и функција јетре код пацијената са AIHом
Sažetak
Objective To analyze the relationships between the ratios of helper T-cell 17/regulatory T-cell (Th17/Treg), serum Leukocyte Cell-Derived Chemotaxin 2 (LCDC-2), and Interferon γ-induced protein 10 kDa (IP-10) and liver function and posttreatment response in patients with autoimmune hepatitis (AIH).
Methods For the case group, 204 AIH patients who were admitted to our hospital between January 2022 and January 2024 were chosen. The control group consisted of an additional 200 healthy people who were examined throughout the same time period. The Th17/Treg ratios, serum LCDC-2 and IP-10 levels, Indicators of liver function were examined between the case and control groups. Pearson correlation analysis was used to analyze the correlations between the Th17/Treg ratios in peripheral blood, serum LCDC-2 levels, IP-10 levels and liver function indicators. Additionally, based on their responses following treatment, all patients were split into two groups: 50 patients had poor responses and 154 patients had good responses. Using multivariate logistic regression, the risk factors for a poor reaction were examined.
Results The Th17/Treg ratio and the serum LCDC-2, IP-10, aspartate aminotransferase (AST), and the case group's alanine aminotransferase (ALT) levels were greater than the control group's (P<0.05). Patients in the case group had reduced Th17/Treg ratios, LCDC-2, IP-10, AST, and ALT levels after 4 weeks of treatment compared to those who started treatment 1 day earlier (P<0.05). Pearson correlation analysis revealed that the levels of AST and ALT were positively correlated with the Th17/Treg, LCDC-2, and IP-10 ratios (P<0.05). Univariate analysis revealed that the Th17/Treg ratio and LCDC-2, IP-10, AST, ALT, and IgG levels were associated with the response of AIH patients after treatment (P<0.05). An increased Th17/Treg ratio was one of the risk variables for poor treatment response in AIH patients, according to multivariate logistic regression analysis, elevated LCDC-2, elevated IP-10, elevated AST, elevated ALT, and elevated IgG (P<0.05).
Conclusion The Th17/Treg ratio, serum LCDC-2, and IP-10 level are closely related to liver function and posttreatment response in patients with AIH. They can be used as biological indicators to assist in diagnosing AIH patients and evaluating the posttreatment response status.
Reference
2.Kang Y, Kuang X, Yan H, Ren P, Yang X, Liu H, Liu Q, Yang H, Kang X, Shen X, Tong M, Li L, Wang X, Guo L, Ma J, Zhang F, Fan W. A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway. mSystems. 2023 Apr 27;8(2):e0112722. doi: 10.1128/msystems.01127-22. Epub 2023 Feb 16. PMID: 36794950; PMCID: PMC10134874.
3.He Y, Ding M, Zhang J, Huang C, Shi J, Wang Y, Tao R, Wu Z, Guo W. Astaxanthin Alleviates Autoimmune Hepatitis by Modulating CD8+ T Cells: Insights From Mass Cytometry and Single-Cell RNA Sequencing Analyses. Adv Sci (Weinh). 2024 Aug;11(30):e2403148. doi: 10.1002/advs.202403148. Epub 2024 Jun 14. PMID: 38874408; PMCID: PMC11321693.
4.Weltzsch JP, Bartel CF, Waldmann M, Renné T, Schulze S, Terziroli Beretta-Piccoli B, Papp M, Oo YH, Ronca V, Sebode M, Lohse AW, Schramm C, Hartl J. Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and cotherapy with allopurinol. Hepatology. 2024 Nov 1;80(5):1026-1040. doi: 10.1097/HEP.0000000000000940. Epub 2024 May 29. PMID: 39162583.
5.Zhang Q, Luo Y, Zheng Q, Zhao H, Wei X, Li X. Itaconate attenuates autoimmune hepatitis via PI3K/AKT/mTOR pathway-mediated inhibition of dendritic cell maturation and autophagy. Heliyon. 2023 Jun 22;9(7):e17551. doi: 10.1016/j.heliyon.2023.e17551. PMID: 37449121; PMCID: PMC10336503.
6.Kuo L, Kuwelker S, Tsai E. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review. Ann Palliat Med. 2023 Nov;12(6):1275-1294. doi: 10.21037/apm-23-250. Epub 2023 Sep 13. PMID: 37731304.
7.Wu W, Tong HM, Li YS, Cui J. Rosacea and autoimmune liver diseases: a two-sample Mendelian randomization study. Arch Dermatol Res. 2024 Aug 20;316(8):549. doi: 10.1007/s00403-024-03331-3. PMID: 39162878; PMCID: PMC11335937.
8.Longhi MS, Zhang L, Mieli-Vergani G, Vergani D. B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis. Autoimmun Rev. 2024 Jul-Aug;23(7-8):103591. doi: 10.1016/j.autrev.2024.103591. Epub 2024 Aug 6. PMID: 39117005; PMCID: PMC11409799.
9.Lin H, Lin J, Pan T, Li T, Jiang H, Fang Y, Wang Y, Wu F, Huang J, Zhang H, Chen D, Chen Y. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction. Cell Death Dis. 2023 Jan 28;14(1):68. doi: 10.1038/s41419-023-05589-3. Erratum in: Cell Death Dis. 2023 May 2;14(5):300. doi: 10.1038/s41419-023-05816-x. PMID: 36709322; PMCID: PMC9884241.
10.Zhu J, Chen H, Cui J, Zhang X, Liu G. Oroxylin A inhibited autoimmune hepatitis-induced liver injury and shifted Treg/Th17 balance to Treg differentiation. Exp Anim. 2023 Aug 7;72(3):367-378. doi: 10.1538/expanim.22-0171. Epub 2023 Mar 13. PMID: 36927981; PMCID: PMC10435359.
11.Zhang W, Lang R. Association between autoimmune liver diseases and chronic hepatitis B: A multivariable Mendelian randomization study in European population. Prev Med. 2024 Jul;184:107984. doi: 10.1016/j.ypmed.2024.107984. Epub 2024 May 3. PMID: 38705484.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Wang CR, Tsai HW, Wu IC. Systemic lupus erythematosus and autoimmune hepatitis overlap disease in a hospitalized systemic lupus erythematosus cohort. J Formos Med Assoc. 2024 Oct;123(10):1110-1114. doi: 10.1016/j.jfma.2024.06.003. Epub 2024 Jun 8. PMID: 38851914.
14.Terziroli Beretta-Piccoli B, Buescher G, Dalekos G, Zachou K, Geerts A, Semmo N, Kolev M, De Martin E, Janik MK, Madaleno J, Lalosevic Stojkovic M, Dumortier J, Vanwolleghem T, Schregel I, Steinmann S, Lacaille F, Sebode M. Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis. J Autoimmun. 2023 Nov;140:103113. doi: 10.1016/j.jaut.2023.103113. Epub 2023 Sep 15. PMID: 37716078.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
16.Pongracz T, Biewenga M, Stoelinga AEC, Bladergroen MR, Nicolardi S, Trouw LA, Wuhrer M, de Haan N, van Hoek B. Autoimmune hepatitis displays distinctively high multiantennary sialylation on plasma N-glycans compared to other liver diseases. J Transl Med. 2024 May 14;22(1):456. doi: 10.1186/s12967-024-05173-z. PMID: 38745252; PMCID: PMC11092172.
17.Xiao Z, Wang S, Luo L, Lv W, Feng P, Sun Y, Yang Q, He J, Cao G, Yin Z, Yang M. Lkb1 orchestrates γδ T-cell metabolic and functional fitness to control IL-17-mediated autoimmune hepatitis. Cell Mol Immunol. 2024 Jun;21(6):546-560. doi: 10.1038/s41423-024-01163-9. Epub 2024 Apr 19. PMID: 38641698; PMCID: PMC11143210.
18.Plagiannakos CG, Hirschfield GM, Lytvyak E, Roberts SB, Ismail M, Gulamhusein AF, Selzner N, Qumosani KM, Worobetz L, Hercun J, Vincent C, Flemming JA, Swain MG, Cheung A, Chen T, Grbic D, Peltekain K, Mason AL, Montano-Loza AJ, Hansen BE; Canadian Network for Autoimmune Liver Disease (CaNAL). Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicenter cohort study. J Hepatol. 2024 Aug;81(2):227-237. doi: 10.1016/j.jhep.2024.03.021. Epub 2024 Mar 24. PMID: 38527524.
19.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
20.Chen TT, Li XQ, Li N, Xu YP, Wang YH, Wang ZY, Zhang SN, Qi M, Zhang SH, Wei W, Wang H, Sun WY. β-arrestin2 deficiency ameliorates S-100-induced autoimmune hepatitis in mice by inhibiting infiltration of monocyte-derived macrophage and attenuating hepatocyte apoptosis. Acta Pharmacol Sin. 2023 Oct;44(10):2048-2064. doi: 10.1038/s41401-023-01103-9. Epub 2023 May 25. PMID: 37225848; PMCID: PMC10545685.
21.Yang X, Li J, Ren M, Pan X, Liu H, Jiang J, Li M, Yang Z, Han B, Ma L, Hao J, Duan Y, Yin Z, Xu Y, Xiang Z, Wu B. Comprehensive analysis of immune signatures in primary biliary cholangitis and autoimmune hepatitis. J Leukoc Biol. 2024 Dec 31;117(1):qiae085. doi: 10.1093/jleuko/qiae085. PMID: 38652703.
22.Granito A, Muratori P, Pappas G, Lenzi M, Czaja AJ, Muratori L. Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells. Clin Exp Immunol. 2024 Aug 9;217(3):233-239. doi: 10.1093/cei/uxae051. PMID: 38902849; PMCID: PMC11310692.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
24.Czaja AJ. Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2024 Nov;18(11):725-743. doi: 10.1080/17474124.2024.2432480. Epub 2024 Dec 2. PMID: 39575891.
25.Yang F, Zhou L, Shen Y, Wang X, Fan X, Yang L. Multiomics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome. J Transl Med. 2024 Feb 29;22(1):214. doi: 10.1186/s12967-024-05029-6. PMID: 38424613; PMCID: PMC10902991.
26.Xiong A, Li S, Dou X, Yao Y. Cyclophosphamide in refractory autoimmune hepatitis and autoimmune hepatitis coexisting extrahepatic autoimmune disorders. Am J Med Sci. 2024 Nov;368(5):446-454. doi: 10.1016/j.amjms.2024.06.007. Epub 2024 Jun 12. PMID: 38876435.
27.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
28.An R, Zhu Z, Chen Y, Guan W, Wang J, Ren H. MSCs Suppress Macrophage Necroptosis and Foster Liver Regeneration by Modulating SP1/SK1 Axis in Treating Acute Severe Autoimmune Hepatitis. Adv Sci (Weinh). 2025 Mar;12(12):e2408974. doi: 10.1002/advs.202408974. Epub 2025 Feb 3. PMID: 39899606; PMCID: PMC11948073.
29.Tanaka A, Notohara K, Tobari M, Abe M, Umemura T, Takahashi A, Tsutsui A, Ito T, Tsuneyama K, Masamune A, Harada KI, Ohira H, Kawano M. A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy. J Gastroenterol. 2025 May;60(5):632-640. doi: 10.1007/s00535-025-02221-3. Epub 2025 Feb 8. PMID: 39921744; PMCID: PMC12014833.
30.Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, Nakamoto N, Takaki A, Kang JH, Joshita S, Suzuki Y, Koike K, Inui A, Tanaka A; Japan Autoimmune Hepatitis Study group. Autoimmune Hepatitis with Metabolic Dysfunction-associated Fatty Liver Disease. Intern Med. 2025 Feb 1;64(3):337-342. doi: 10.2169/internalmedicine.3112-23. Epub 2024 Jul 4. PMID: 38960681; PMCID: PMC11867740.
31.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
32.Zhou P, Tao K, Zeng L, Zeng X, Wan Y, Xie G, Liu X, Zhang P. IRG1/Itaconate inhibits proliferation and promotes apoptosis of CD69+CD103+CD8+ tissue-resident memory T cells in autoimmune hepatitis by regulating the JAK3/STAT3/P53 signaling pathway. Apoptosis. 2024 Oct;29(9-10):1738-1756. doi: 10.1007/s10495-024-01970-5. Epub 2024 Apr 19. PMID: 38641760.
33.Zouridis S, Oo YH, Syn WK. Role of Sirolimus and Rituximab in the Treatment of Autoimmune Hepatitis. ACG Case Rep J. 2024 Jul 11;11(7):e01414. doi: 10.14309/crj.0000000000001414. PMID: 38994192; PMCID: PMC11239162.
34.Lin J, Lin HW, Wang YX, Fang Y, Jiang HM, Li T, Huang J, Zhang HD, Chen DZ, Chen YP. FGF4 ameliorates the liver inflammation by reducing M1 macrophage polarization in experimental autoimmune hepatitis. J Transl Med. 2024 Aug 2;22(1):717. doi: 10.1186/s12967-024-05219-2. PMID: 39095789; PMCID: PMC11295337.
35.Wang S, Huang Z, Nie S, Chen Y, Lei Y, Tu W, Luo M, Zhang ZG, Tian DA, Gong J, Liu M. Unveiling the interplay between hepatocyte SATB1 and innate immunity in autoimmune hepatitis. Int Immunopharmacol. 2025 Jan 10;144:113712. doi: 10.1016/j.intimp.2024.113712. Epub 2024 Dec 3. PMID: 39626541.
36.Lyu Z, Huang B, Zhang J, Qian Q, Pu X, Cui N, Ou Y, Li B, You Z, Lian M, Tang R, Chen W, Zhao Z, Hou J, Gershwin ME, Zhang H, Xia Q, Ma X. Suppression of YTHDF2 attenuates autoimmune hepatitis by expansion of myeloid-derived suppressor cells. J Autoimmun. 2023 Feb;135:102993. doi: 10.1016/j.jaut.2023.102993. Epub 2023 Jan 13. PMID: 36642058.
Sva prava zadržana (c) 2026 Wei Zhang, Anqing Luo, Yanfang Wei, Xue Su, Zhengdeng Li, Huimei Yao, Xin Tian, Sheng Zheng
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.